LAS 37779
Alternative Names: LAS-37779Latest Information Update: 19 Mar 2008
At a glance
- Originator Almirall-Prodesfarma
- Developer Laboratorios Almirall
- Class Antipsoriatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 30 Jun 2007 Phase-II clinical trials in Psoriasis in Spain (unspecified route)
- 04 Aug 2005 Phase-I clinical trials in Psoriasis in Spain (unspecified route)